ATH

The $Bobby Token launches at Consensus 2024; Announces Kennedy Campaign Community Activator, Kyle Kemper, as Advisor

Retrieved on: 
木曜日, 5月 30, 2024

The $Bobby token has sponsored Kyle Kemper's Kennedy24 bus, which will be parked in front of the Consensus event venue.

Key Points: 
  • The $Bobby token has sponsored Kyle Kemper's Kennedy24 bus, which will be parked in front of the Consensus event venue.
  • The team, with Kyle at the fore, will be handing out Kennedy24 and $Bobbymerchandise to the event's crypto-enthusiast attendees, and are planning a few other surprises.
  • In a market crowded with political meme coins, the $Bobby Token stands out by having real substance behind it.
  • Kyle Kemper, a renowned figure in the cryptocurrency space, has joined the $Bobby Token team as an advisor.

Meet Brett ($BRETT): The Leading Memecoin and Official Mascot of the Base Chain

Retrieved on: 
木曜日, 5月 30, 2024

Madrid, Spain, May 29, 2024 (GLOBE NEWSWIRE) -- The world of cryptocurrency is thrilled to welcome Brett ($BRETT), the newest and most exciting memecoin on the Base Chain.

Key Points: 
  • Madrid, Spain, May 29, 2024 (GLOBE NEWSWIRE) -- The world of cryptocurrency is thrilled to welcome Brett ($BRETT), the newest and most exciting memecoin on the Base Chain.
  • Brett has distinguished itself as the top memecoin on the Base Chain, setting a new all-time high (ATH) of 850 million.
  • This milestone marks Brett as the first memecoin to reach such heights on the Base Chain, demonstrating the strong community and investor interest it has attracted.
  • Now, he has found a new life on the Base blockchain, becoming the blue mascot of the blue chain.

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

Retrieved on: 
木曜日, 5月 30, 2024

MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast today on Thursday, 30 May 2024 in Australia / Wednesday, 29 May 2024 in the United States. Details are listed below and registration is required.

Key Points: 
  • Details are listed below and registration is required.
  • The call will feature Alterity’s CEO Dr. David Stamler who will discuss the bioMUSE Natural History Study results and their impact on the endpoints for the ATH434-202 Phase 2 clinical trial.
  • Joining the call will be key opinion leader Daniel Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University Medical Center.
  • Dr. Claassen is the Principal Investigator of bioMUSE and the Coordinating Investigator of the ATH434-201 Phase 2 clinical trial.

Kabosu has passed on! Meet NOTINU, the new face of dog memes in the crypto industry

Retrieved on: 
水曜日, 5月 29, 2024

Presale Success on TON Inu Launchpad:

Key Points: 
  • Presale Success on TON Inu Launchpad:
    Their journey began on April 19th, 2024, with an extraordinary presale event on the TON Inu Launchpad.
  • In less than 20 minutes, they raised an impressive 50,000 TON, equivalent to over $300k.
  • This monumental success not only reflects the strength of Notcoin Inu project but also underscores their prominence within the broader TON ecosystem.
  • On Monday, April 22nd, they embarked on the next phase of their journey by launching on Ston.fi Dex.

Breaking News: AthenaDexFi Launches Exciting Pre-Sale for ATH Token, Unveiling Lucrative Investment Opportunities with Airdrop Bonus

Retrieved on: 
金曜日, 5月 17, 2024

Today, AthenaDexFi proudly announces the launch of its highly anticipated pre-sale for ATH Token, promising investors unparalleled profitability and peace of mind, along with an exclusive airdrop bonus.

Key Points: 
  • Today, AthenaDexFi proudly announces the launch of its highly anticipated pre-sale for ATH Token, promising investors unparalleled profitability and peace of mind, along with an exclusive airdrop bonus.
  • With a commitment to transparency and quality, AthenaDexFi ensures that investors can confidently navigate the complex world of finance.
  • With projects in their infancy and meme coins curated in one convenient location, users can explore new investment opportunities with ease.
  • In conclusion, AthenaDexFi stands as a beacon of opportunity in the realm of decentralized finance, offering investors a gateway to lucrative investment opportunities with the utmost confidence and security.

Alpha Sigma Capital Research Releases April Report on ASC AI Index

Retrieved on: 
木曜日, 5月 9, 2024

Tampa, FL, May 09, 2024 (GLOBE NEWSWIRE) -- Alpha Sigma Capital Research (ASCR), a subsidiary of Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the April report on ASC AI Index (AAI).

Key Points: 
  • Tampa, FL, May 09, 2024 (GLOBE NEWSWIRE) -- Alpha Sigma Capital Research (ASCR), a subsidiary of Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the April report on ASC AI Index (AAI).
  • AAI tracks the price performance of the top tokens in the AI sector, using a rules-based criteria designed to reflect the landscape of AI tokens.
  • The index includes the top 30 tokens that meet the minimum criteria of market capitalization, daily trading volume, and quality of exchange venues.
  • To receive monthly reports on ASC AI Index to your inbox, subscribe to alphasigmacapitalresearch.substack.com.

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Retrieved on: 
水曜日, 5月 8, 2024

MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.

Key Points: 
  • The DMC conducted its prespecified review of unblinded clinical data from study participants.
  • The plan for the DMC to review clinical data from the trial has been cleared with the U.S. Food and Drug Administration.
  • “We are pleased to report that the Data Monitoring Committee for our ATH434-201 Phase 2 clinical trial has again determined that there are no safety concerns and that the study can continue as planned,” said David Stamler, M.D., Chief Executive Officer of Alterity.
  • Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091 .

Cloudbench and Arhasi have announced a mutual investment in each other, deepening their AI partnership

Retrieved on: 
火曜日, 5月 7, 2024

The decision to strengthen the partnership underscores the joint commitment to provide enhanced services to clients implementing AI initiatives, coinciding with a surge in demand for AI services.

Key Points: 
  • The decision to strengthen the partnership underscores the joint commitment to provide enhanced services to clients implementing AI initiatives, coinciding with a surge in demand for AI services.
  • "It's been an extraordinary beginning to the year for Cloudbench, marked by launching ourselves as a top AI and Web3-focused Google partner and establishing a deeper strategic partnership with Arhasi through our mutual investment”, said Tom Richer , Founder of Cloudbench.
  • "Since its launch, Cloudbench has focused on emerging technology, assisting startups and midmarket clients across diverse sectors in unlocking the full potential of AI.
  • Cloudbench and Arhasi are well poised to spearhead this future, actively shaping and enabling its evolution.”

Powerledger and MYTILINEOS Collaborate for Clean Energy PPA Tracking and Smart Sourcing

Retrieved on: 
水曜日, 4月 17, 2024

Powerledger partners with Greek energy and metals company, MYTILINEOS (through Protergia), to introduce, for the first time, one of its kind energy provenance tracking and tracing solutions in Greece.

Key Points: 
  • Powerledger partners with Greek energy and metals company, MYTILINEOS (through Protergia), to introduce, for the first time, one of its kind energy provenance tracking and tracing solutions in Greece.
  • Zug, Switzerland--(Newsfile Corp. - April 17, 2024) - Powerledger in partnership with MYTILINEOS Energy & Metals (RIC: MYTr.AT) (ATH: MYTIL) (OTC Pink: MYTHY) (MYTILINEOS) through Protergia , introduces energy provenance tracking and tracing solutions in Greece.
  • Powerledger - MYTILINEOS partnership boasts several key features as following:
    It allows consumers to trace, visualise near real-time energy using blockchain and AI.
  • "The Powerledger blockchain meticulously tracks and traces the supplied energy from its generation source to its point of consumption, from smart meter data.

$BENJI Token Sets New Standards on Base Chain with $30 Million Market Cap in 24 Hours

Retrieved on: 
水曜日, 4月 10, 2024

New York, New York--(Newsfile Corp. - April 10, 2024) - Basaenji's token $BENJI achieved new heights after surging to a $30 million market cap in the first 24 hours.

Key Points: 
  • New York, New York--(Newsfile Corp. - April 10, 2024) - Basaenji's token $BENJI achieved new heights after surging to a $30 million market cap in the first 24 hours.
  • $BENJI, the brand new addition to the Base Chain surroundings, has emerged as a premiere token with an unprecedented surge to $30 million market cap on the first day.
  • $BENJI's market cap rose to an impressive $30 million within the first 24 hours of its launch, and an ATH of 57M in its first week stands as a testament to the power of network-backed projects.
  • With unwavering dedication to excellence, BENJI has set up itself as a pioneer in branding and network outreach.